Author Interviews, Opiods / 27.06.2021
Initiating Monthly Buprenorphine Injection After Single Dose of Sublingual Buprenorphine
This study and abstract presentation evaluated opioid withdrawal symptoms, safety and tolerability of initiating SUBLOCADE 300 mg one hour after administering a single dose of 4 mg transmucosal (sublingual) buprenorphine (BUP-TM).
26 participants received BUP-TM, 24 follow by SUBLOCADE injection, and 20 completed the study.
Participants were evaluated for opioid withdrawal symptoms as well as safety and tolerability of SUBLOCADE 300 mg.
(more…)
Background: To identify individual-level factors associated with COVID-19-related impacts on recovery in 216 participants originally enrolled in the SUBLOCADE® (buprenorphine extended-release) clinical program.
Within the fifteen-month study 216 participants, during the period of September 2021 through January 2021, were asked how the COVID-19 crisis affected their recovery from substance use, utilizing self-reported measures.